Publique un comentario 
Sobre la asociación entre el hígado graso no alcohólico y la insulinorresistencia
Texto completo:
PDFResumen
53.0 ± 12.4 años; Índice de Masa Corporal: 30.4 ± 4.6 Kg.m-2) diagnosticados con HGNA (Afectación: Grave: 6.0%; Moderada: 54.0%; Leve: 40.0%) mediante ultrasonografía (US) en el Servicio de Gastroenterología del Hospital Clínico quirúrgico “Hermanos Ameijeiras” (La Habana, Cuba). Material y método: Se determinaron las concentraciones séricas de triglicéridos, colesterol total y fraccionado, enzimas hepáticas, y glucosa e insulina en ayunas y 2 horas después de una sobrecarga oral de glucosa (SCOG). Adicionalmente, se calcularon los cocientes ASAT/ALAT y GGT/ASAT; y los índices HOMA-IR, HOMA-β, y de sensibilidad a la insulina (ISI). Se evaluó la naturaleza de las asociaciones entre las variables bioquímicas determinadas y la gravedad del HGNA. Resultados: El HGNA se asoció con valores elevados de la actividad GGT (y por extensión, el índice GGT/ASAT). Igualmente, el HGNA se asoció con cifras elevadas de glucosa en ayunas y 2 horas después de la SCOG. El HGNA se acompañó también de incremento del producto plasmático Glucosa*Insulina en ayunas (dado por el comportamiento del índice HOMA-R) y después de la SCOG (como sugiere la disminución del índice IS). Conclusiones: En el HGNA concurren daño hepático y resistencia a la insulina. Estos 2 factores actuando de
conjunto pueden resultar en daño orgánico permanente.
Palabras clave
Referencias
Del Ben M, Polimeni L, Baratta F, Pastori D, Loffredo L, Angelico F. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:8341-50.
Basaranoglu MI, Ormeci N. Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management. Turk J Gastroenterol 2014;25:127-32.
Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello S. Insulin resistance, the metabolic syndrome, and
nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005;90:1578-82.
Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64.
Herrera A, Nasiff A, Arus E, Cand C, León N. Hígado graso. Enfoque diagnóstico y terapeútico. Rev Cubana Med 2007;46:1-12. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232007000100009. Fecha de última
visita: 5 de Mayo del 2016.
Moreno D. Epidemiología e historia natural de la hepatología grasa no alcohólica primaria. Gastroenterol
Hepatol 2006;29:244-54.
Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E. Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition
Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45.
Schuppan D, Schattenberg JM. Nonalcoholic steatohepatitis: Pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013;28:68-76.
Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y; et al. Prevalence of nonalcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141-5.
Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez RM; et al. Nonalcoholic fatty liver disease and its
association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int
;29:82-8.
Lizardi J, Becerra I, Chávez NC, Ramos ME, Uribe M. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Rev Gastroenterol Mex 2006;71:453-9.
Laclé A, Esquivel M, Madrigal M, Alpízar MC. Prevalencia de hígado graso no alcohólico en personas diabéticas tipo 2. Acta Méd Costarric 2014;56(1):0-0. Disponible en:
http://www.redalyc.org/pdf/434/43430087004.pdf. Fecha de última visita: 5 de Mayo del 2016.
Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral
antidiabetic agents. Diabetes Care 1999;2:1067-71.
Younossi ZM, Gramlich T, Matteoni CA, Boparal N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5.
Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C; et al. Global, regional, and national prevalence
of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2014;384(9945):766-81.
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014;28:637-53.
Tarantino G. Non-alcoholic fatty liver disease, obesity and other illnesses. Clin Invest Medicine 2008;31:290-5.
Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State of the art. World J
Gastroenterol 2014;20:13306-24.
Targher G, Byrne CD. Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications [Clinical review]. J Clin Endocrinol Metab 2013;98:483-95.
Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance, and features of metabolic syndrome:
Relationships with coronary artery calcium in 10,153 people. Diabetes Care 2012;35:2359-64.
Castro M, Zaineff D, Ramírez JC, Escobedo J. Prevalencia de hígado graso no alcohólico en individuos con síndrome metabólico. Cir Cir 2012;80:128-33. Disponible en: http://www.scielo.sa.cr/scielo.php?script
=sci_nlinks&ref=060662&pid=S0001-6002201400010000400022&lng=en. Fecha de última visita: 5 de Mayo del 2016.
Castro Sansores CJ, Hernández Escalante V, Arjona Villicaña R. Prevalencia de Síndrome metabólico en
sujetos adultos que viven en Mérida, Yucatán, México. Rev Biomed 2011;22:49-58. Disponible en: http://www.revbiomed.uady.mx/pdf/rb112222.pdf. Fecha de última visita: 21 de Septiembre del 2015.
Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stal P, Kechagias S. Fibrosis stage is the strongest predictor
for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
Day CP, James OF. Steatohepatitis: A tale of two hits? Gastroenterology 1998;114:842-5.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43(2 Suppl
:S99-S112.
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty
connection. Hepatology 2010;51:1820-32.
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 2009;58:1538-44.
Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR; et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-1602.
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other
clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatrics 2003;143:500-5.
Pérez LA, Vilar E, Martínez L, Calzadilla L. Enfermedad hepática por depósitos grasos. Una perspectiva actual.
Acta Gastroenterol Latinoam 2013;43:254-60. Disponible en: http://www.redalyc.org/pdf/1993/199329342016.pdf. Fecha de última visita: 20 de Julio del 2015.
Ministerio de Salud Pública. República de Cuba. Anuario estadístico 2011. Disponible en: http://www.sld.cu/sitios/dne/. Fecha de última visita: 5 de Mayo del 2016.
Ministerio de Salud Pública. República de Cuba. Anuario estadístico 2012. Disponible en: http://www.sld.cu/sitios/dne/. Fecha de última visita: 5 de Mayo del 2016.
Ministerio de Salud Pública. República de Cuba. Anuario estadístico 2015. Disponible en: http://www.sld.cu/sitios/dne/. Fecha de última visita: 5 de Mayo del 2016.
Wasada T, Kasahara T, Wada J, Jimba S, Fujimaki R, Nakagami T. Hepatic steatosis rather than visceral adiposity is more closely associated with insulin
resistance in the early stage of obesity. Metabolism 2008;57:980-5.
Calderín RO, Domínguez C, Velbes PE, Pérez LA, Cabrera E, Orlandi N. Insulinorresistencia e hígado graso no alcohólico, ¿existe relación causa-efecto entre ambas condiciones? Rev Cubana Endocrinol 2009;20(1):0-0. Disponible en: http://www.bvs.sld.cu/revistas/end/vol20
_1_09/end08109.htm. Fecha de última visita: 20 de Julio del 2015.
Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2
diabetes in Korean adults. Diabet Med 2008;25:476-81.
Sung KC, Kim SH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab 2011;96:1093-7.
González E, Pascual I, Laclaustra GM, Casanova JA. Síndrome metabólico y diabetes mellitus. Rev Esp Cardiol 2005;5:3-7.
Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010;1801:299-310.
Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating
interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-9.
Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G. Enhancement in liver SREBP-1c/PPARalpha
ratio and steatosis in obese patients: Correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009;1792:1080-6.
Weiner JS, Lourie JA. Human biology. A guide to field methods. International Biological Program. Handbook number 9. Blackwell Scientific Publications. Oxford: 1969.
Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Second Edition. Human Kinetics Books. Champaign [Illinois]: 1991. Pp 44-47.
Martínez Sanz JM, Ortiz Moncada MR. Antropometría. Manual básico para estudios de salud pública, nutrición comunitaria y epidemiología nutricional. Editorial Prácticum. Madrid: 2013.
Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972;3(826):566-9.
WHO Working Group. Use and interpretation of anthropometric indicators of nutritional status. Bulletin
WHO 1986;64:929-41.
Seidel JC, Deurenberg P. Fat distribution of overweight persons in relation to morbidity and subjective health. Int J
Obesity 1985;9:363-74.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in
plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
Duncan MH, Singh BM, Wise PH, Carter G, Alaghband-Zadeh J. A simple measure of insulin resistance. Lancet 1995;346:120-1.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
Belfiore F, Iannello S, Volpicelli G. Insulin sensitivity indices calculated from basal and OGTT-induced insulin,
glucose, and FFA levels. Mol Genet Metab 1998;63(2):134-41.
Santana Porbén S, Martínez Canalejo H. Manual de Procedimientos Bioestadísticos. Segunda Edición. EAE
Editorial Académica Española. ISBN-13:9783659059629. ISBN-10: 3659059625. Madrid: 2012.
Santana Porbén S, Martínez Canalejo H. Manual de Estadísticas no Paramétricas. Editorial Publicia. Saarbrücken: 2013. ISBN: 978-3-639-55468-7. Madrid: 2012.
Gariani K, Philippe J, Jornayvaz FR. Non-alcoholic fatty liver disease and insulin resistance: From bench to
bedside. Diabetes Metab 2013;39:16-26.
Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2
diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352-6.
Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of
metabolic disorders. J Gastroenterol Hepatol 2007;22:1086-91.
Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A.
Nonalcoholic Fatty liver: A possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci 2013;14:22933-66.
Maggiore G, Bernard O, Hadchouel M, Lemonnier A, Alagille D. Diagnostic value of serum [gamma]-glutamyl
transpeptidase activity in liver diseases in children. J Pediatric Gastroenterol Nutrition 1991;12:21-6.
Tarantino G, Colao A, Capone D, Conca P, Tarantino M, Grimaldi E; et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with nonalcoholic fatty liver disease. J Biol Regulators Homeostatic Agents 2010;25:47-56.
Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: Falls in gamma-glutamyl
transferase concentrations are associated with histologic improvement. Obesity Surgery 2006;16:1278-86.
Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E; et al. Risk of severe liver disease in
nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and Diabetes. Hepatology 2008;48:792-8.
Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a
marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diab
Metab Res Rev 2006;22:437-43.
Nichols CG, Koster JC, Remedi MS. Beta‐cell hyperexcitability: From hyperinsulinism to Diabetes. Diab Obes Metab 2007;9:81-8.
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 Diabetes mellitus. J Clin Invest 1999;104:787-94.
Bagdade JD, Porte Jr D, Brunzell JD, Bierman EL. Basal and stimulated hyperinsulinism: Reversible metabolic sequelae of obesity. J Lab Clin Med 1974;83:563-9.
Kim SH, Reaven GM. Insulin resistance and hyperinsulinemia: You can´t have one without the other. Diabetes Care 2008;31:1433-8.
Belfiore F, Iannello S. Insulin resistance and its relevance to treatment. En: New concepts in Diabetes and its treatment. Karger Publishers. London: 2000. pp. 38-55.
Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW; et al. Quantification of the relationship between insulin sensitivity and beta-cell
function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-72.
Bazotte RB, Silva LG, Schiavon FP. Insulin resistance in the liver: Deficiency or excess of insulin? Cell Cycle 2014;
:2494-2500.
Quon MJ. Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J Clin Endocrinol
Metab 2001;86:4615-17.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95.
Meier JJ, Breuer TGK, Bonadonna RC, Tannapfel A, Uhl W, Schmidt WE; et al. Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia 2012;55:1346-54.
Piñeiro R, Fernández JE. Hígado graso no alcohólico como señal de aterosclerosis. Rev Cubana Invest Bioméd 2013;32:1-7. Disponible en: http://scielo.sld.cu/pdf/ibi/v32n1/ibi01113.pdf. Fecha de última visita: 16 de Mayo del 2016.
Uribe M. Esteatosis hepática, obesidad y comorbilidades. Rev Gastroenterol Mex 2008;73:22-5.
Van der Poorten D, Milner KL, Hui J, Hodge A, Trenell MI, Kench JG. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology. 2008; 48:449-57.
Márquez R, Sbardella V, Viera L. Relación entre adiposidad visceral, circunferencia abdominal e
insulinorresistencia en pacientes con hígado graso no alcohólico. Revista Gen 2011;65:323-7. Disponible en:
http://www.scielo.org.ve/pdf/gen/v65n4/art07.pdf. Fecha de última visita: 16 de Mayo del 2016.
Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes 2012;19:81-7.
Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011;4:249-63.
Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F; et al. Diagnostic value of biochemical
markers (NashTest) for the prediction of non-alcohol steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6(1):34. Disponible en:
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-6-34. Fecha de última visita: 5 de Mayo del 2016.
Reaven GM. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: The
price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am 2005;34:49-62.
Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M; et al. Prevalence of nonalcoholic fatty liver
disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011;140:124-31.
Musso G. Gambino R, Cassader M; et al. Meta-analysis: Natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
Bedogni G, Miglioli L, Masutti F, Castiglione A, Croce LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: The Dionysos study.
Hepatology 2007;46:1387-91.
Enlaces refback
- No hay ningún enlace refback.
La revista está: Certificada por el CITMA
La revista es de acceso abierto y gratuito.